Psoriatic arthritis secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 9: | Line 9: | ||
* There are no established secondary preventive measures for psoriatic arthritis. | * There are no established secondary preventive measures for psoriatic arthritis. | ||
* Patients are monitored regularly for [[disease]] activity, [[:Category:Drugs|drug]] efficacy, [[Adverse effect (medicine)|adverse effects]] and associated [[Comorbidity|comorbid conditions]].<ref name="pmid14730596">{{cite journal |vauthors=Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W |title=Assessment of patients with psoriatic arthritis: a review of currently available measures |journal=Arthritis Rheum. |volume=50 |issue=1 |pages=24–35 |date=January 2004 |pmid=14730596 |doi=10.1002/art.11417 |url=}}</ref> | * Patients are monitored regularly for [[disease]] activity, [[:Category:Drugs|drug]] efficacy, [[Adverse effect (medicine)|adverse effects]] and associated [[Comorbidity|comorbid conditions]].<ref name="pmid14730596">{{cite journal |vauthors=Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W |title=Assessment of patients with psoriatic arthritis: a review of currently available measures |journal=Arthritis Rheum. |volume=50 |issue=1 |pages=24–35 |date=January 2004 |pmid=14730596 |doi=10.1002/art.11417 |url=}}</ref> | ||
* The following measures are helpful to prevent cardiovascular complications associated with psoriatic arthritis.<ref name="pmid27697765">{{cite journal |vauthors=Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, Kvien TK, Dougados M, Radner H, Atzeni F, Primdahl J, Södergren A, Wallberg Jonsson S, van Rompay J, Zabalan C, Pedersen TR, Jacobsson L, de Vlam K, Gonzalez-Gay MA, Semb AG, Kitas GD, Smulders YM, Szekanecz Z, Sattar N, Symmons DP, Nurmohamed MT |title=EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update |journal=Ann. Rheum. Dis. |volume=76 |issue=1 |pages=17–28 |date=January 2017 |pmid=27697765 |doi=10.1136/annrheumdis-2016-209775 |url=}}</ref> | |||
**Smoking cessation | |||
**Dietary control to prevent hyperlipidemia, hypertension. | |||
**Exercise | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 14:22, 16 May 2018
|
Psoriatic arthritis Microchapters | |
|
Diagnosis | |
|---|---|
|
Treatment | |
|
Case Studies | |
|
Psoriatic arthritis secondary prevention On the Web | |
|
American Roentgen Ray Society Images of Psoriatic arthritis secondary prevention | |
|
Risk calculators and risk factors for Psoriatic arthritis secondary prevention | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chandrakala Yannam, MD [2]
Overview
There are no established secondary preventive measures for psoriatic arthritis.
Secondary prevention
- There are no established secondary preventive measures for psoriatic arthritis.
- Patients are monitored regularly for disease activity, drug efficacy, adverse effects and associated comorbid conditions.[1]
- The following measures are helpful to prevent cardiovascular complications associated with psoriatic arthritis.[2]
- Smoking cessation
- Dietary control to prevent hyperlipidemia, hypertension.
- Exercise
References
- ↑ Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W (January 2004). "Assessment of patients with psoriatic arthritis: a review of currently available measures". Arthritis Rheum. 50 (1): 24–35. doi:10.1002/art.11417. PMID 14730596.
- ↑ Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, Kvien TK, Dougados M, Radner H, Atzeni F, Primdahl J, Södergren A, Wallberg Jonsson S, van Rompay J, Zabalan C, Pedersen TR, Jacobsson L, de Vlam K, Gonzalez-Gay MA, Semb AG, Kitas GD, Smulders YM, Szekanecz Z, Sattar N, Symmons DP, Nurmohamed MT (January 2017). "EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update". Ann. Rheum. Dis. 76 (1): 17–28. doi:10.1136/annrheumdis-2016-209775. PMID 27697765.